The FDA has approved the aura6000 proximal hypoglossal nerve stimulation device for adult patients with moderate to severe obstructive sleep apnea. The system was developed by LivaNova and the announcement of the approval came on Thursday. It is a new generation nerve stimulator intended for the treatment of obstructive sleep apnea. Approval took place according to the pre-market route. The device stimulates the hypoglossal nerve, which affects the muscles of the tongue. It is implantable and designed specifically for the mentioned group of patients. The manufacturer LivaNova informed about this milestone.